

Product Data Sheet

Product Name: EW-7197

Cat. No.: GC13354

Chemical Properties

Cas. No. 1352608-82-2

Chemical Name N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline

SMILES CC1=NC(C2=C(N=C(N2)CNC3=CC=CC=C3F)C(C=C4)=CN5C4=NC=N5)=CC=C1

Formula $C_{22}H_{18}FN_7$

M.Wt 399.42


Solubility $\geq 39.9\text{mg/mL}$ in DMSO

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Protocol

Cell experiment [1]:

Cell lines BV-2 microglial cells

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Preparation Method The BV-2 microglial cells were pretreated with 100nM of TGF- β R1 inhibitors EW-7197 for 4h followed by the exposure of 2 μ M A β for 24h.

Reaction Conditions 100nM; 4h

Applications Pretreatment with 100nM of EW-7197 for 4h prior to exposure of 2 μ M A β resulted in a significant attenuation in the production of proinflammatory cytokines TNF- α and IL-1 β compared with the A β control group.

Animal experiment [2]:

Animal models C57BL/6 male mice

Preparation Method Mice were randomly divided into three groups (n = 6 for each group). (a) A control group received drinking water for 10 days. (b) A colitis group that received 1% (w/v) dextran sulfate sodium (DSS) in drinking water for 7 days and then normal drinking water for the next 3 days. (c) The EW-7197 treated mice received DSS 1% (w/v) from Day 1–7, and EW-7197 (5mg/kg/day; oral gavage) from Day 3–10.

Dosage form 5mg/kg/day; oral gavage; Day 3-10

Applications EW-7197 elicited its anticolitis properties partially by regulating inflammatory gene expression as well as oxidant/antioxidant balance in colitis mice.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

References:

- [1] Tiong S Q, Mohgan R N, Quek J Y, et al. Inhibition of the Transforming Growth Factor- β Signaling Pathway Confers Neuroprotective Effects on Beta-Amyloid-Induced Direct Neurotoxicity and Microglia-Mediated Neuroinflammation. *Neurol Res Int*. 2025 Jan 30;2025:8948290.
- [2] Binabaj M M, Asgharzadeh F, Avan A, et al. EW-7197 prevents ulcerative colitis-associated fibrosis and inflammation. *J Cell Physiol*. 2019 Jul;234(7):11654-11661.

Background

EW-7197 is an orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)- β receptor type 1 (TGFB β R1), also known as activin receptor-like kinase 5 (ALK5) with IC₅₀ value of 12.9nM^[1]. EW-7197 exerts the anti-inflammatory and anti-fibrotic properties ^{[2][4][5]}. EW-7197 has also demonstrated robust antitumor activity across various cancer models, including pancreatic cancer and breast cancer^{[3][6]}.

In vitro, pretreated SH-SY5Y neuroblastoma cells with EW-7197 (50nM, 100nM, 150nM) for 24h performed neuroprotective effect on SH-SY5Y against A β -induced neurotoxicity. Pretreated BV-2 microglial cells with 100nM EW-7197 for 4h prior to exposure of 2 μ M A β resulted in a significant attenuation in the production of proinflammatory cytokines (TNF- α and IL-1 β) compared with the A β control group. The results show that EW-7197 could be an alternative approach to selectively modulate A β -induced neuroinflammatory responses in microglia of Alzheimer's disease patients by targeting TGF- β signaling^[2]. Pancreatic cancer cell lines MIA PaCa-2 and PANC-1 treated with EW-7197 (10 μ M) for 72 hours inhibited cell viability and proliferation. The therapeutic effect of EW-7197 on pancreatic cancer was significantly enhanced when applied in combination with gemcitabine (0.1 μ M) for an additional 48 hours^[3]. Hepatocellular fibrosis was induced in human hepatic stellate cells (LX-2) and Alpha mouse liver 12 (AML12) mouse hepatocytes using TGF- β (2ng/mL). The cells were then treated with EW-7197 (0.5 μ M) for 24h. EW-7197 demonstrated significant anti-fibrotic effects in both LX-2 and AML12 cells, significantly reducing the expression of fibrosis markers (such as α -SMA, Col I, and p-SMAD2/3) induced by TGF- β and partially restoring the activity of Erk and Akt^[4].

In vivo, EW-7197 (5mg/kg/day) administered via oral gavage in dextran sulfate sodium (DSS)-induced colitis mice for 7 days ameliorated colitis clinical symptoms and attenuated histological

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

damage to colon tissue by regulating inflammatory gene expression as well as oxidant/antioxidant balance in colitis mice^[5]. EW-7197 (10mg/kg) or vehicle (simulated gastric fluid) was given orally five times a week for 2 weeks into rat Models of Peyronie's Disease (PD). EW-7197 induced significant regression of fibrotic plaques in PD rats in vivo through reduced infiltration of inflammatory cells and reduced expression of phospho-Smad2, which recovered erectile function^[6]. EW-7197 (2.5mg/kg) were orally administered into 4T1-Luc allograft BALB/c syngeneic mouse model for two weeks to investigate whether EW-7197 blocks radiation-induced TGF- β signaling in breast cancer. The results showed that EW-7197 treatment overcame the limitations of radiotherapy in breast cancer treatment by inhibiting oxidative stress, EMT, cancer stem cell (CSC), and fibrosis^[7].

References:

- [1] Son J Y, Park S Y, Kim S J, et al. EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis. *Mol Cancer Ther.* 2014 Jul;13(7):1704-16.
- [2] Tiong S Q, Mohgan R N, Quek J Y, et al. Inhibition of the Transforming Growth Factor- β Signaling Pathway Confers Neuroprotective Effects on Beta-Amyloid-Induced Direct Neurotoxicity and Microglia-Mediated Neuroinflammation. *Neurol Res Int.* 2025 Jan 30:2025:8948290.
- [3] Lee J E, Lee P, Yoon Y C, et al. EW-7197, TGF- β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer. *Biomed Pharmacother.* 2023 Jun;162:114716.
- [4] Ha K B, Lee E S, Park N W, et al. Beneficial Effects of a Curcumin Derivative and Transforming Growth Factor- β Receptor I Inhibitor Combination on Nonalcoholic Steatohepatitis. *Diabetes Metab J.* 2023 Jul;47(4):500-513
- [5] Binabaj M M, Asgharzadeh F, Avan A, et al. EW-7197 prevents ulcerative colitis-associated fibrosis and inflammation. *J Cell Physiol.* 2019 Jul;234(7):11654-11661.
- [6] Song K M, Chung D Y, Choi M J, et al. EW-7197, a Novel, Orally Bioavailable Activin Receptor-Like Kinase 5 Inhibitor, Promotes Regression of Fibrotic Plaques in a Rat Model of Peyronie's Disease. *World J Mens Health.* 2020 Oct;38(4):552-563.
- [7] Park J Y, Choi J W, Cho I Y, Sheen Y Y. Radiotherapy-induced oxidative stress and fibrosis in breast cancer are suppressed by vactosertib, a novel, orally bioavailable TGF- β /ALK5 inhibitor. *Sci Rep.* 2022 Sep 27;12(1):16104.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA